1921
Volume 75, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Primaquine phosphate has been used for preventing relapse of and malaria since the early 1950s, based on its ability to kill latent (hypnozoite) and developing liver stages of these parasites. There are three uses for primaquine in malaria: radical cure of established infection with or malaria; presumptive anti-relapse therapy (PART; terminal prophylaxis) in persons with extensive exposure to these parasites; and primary prophylaxis against all malaria species. All persons for whom primaquine is being considered must have a glucose-6-phosphate dehydrogenase (G6PD) enzyme level checked before use, and persons who have a deficiency of G6PD must not take primaquine for prophylaxis or PART. The recommended adult dose for PART based on clinical trials and expert opinion is 30 mg base daily for 14 days, started on return from a malarious region and overlapping with a blood schizonticide. The adult dose for primary prophylaxis is 30 mg daily begun 1 day before travel and continued for 7 days after return. This review will examine the evidence for these recommendations.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2006.75.402
2006-09-01
2019-05-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/75/3/0750402.html?itemId=/content/journals/10.4269/ajtmh.2006.75.402&mimeType=html&fmt=ahah

References

  1. Kish MA, 2001. Guide to development of practice guidelines. Clin Infect Dis 32 : 851–854. [Google Scholar]
  2. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Jeffery GM, 1954. The effect of continuous and intermittent primaquine therapy on the relapse rate of chesson strain vivax malaria. J Lab Clin Med 44 : 429–438. [Google Scholar]
  3. Baird JK, Wiady I, Sutanihardja A, Suradi, Purnomo, Basri H, Sekartuti, Ayomi E, Fryauff DJ, Hoffman SL, 2002. Short report: Therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 66 : 659–660. [Google Scholar]
  4. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ, 1994. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169 : 932–935. [Google Scholar]
  5. Centers for Disease Control and Prevention, Kozarsky PE, Arguin PM, Navin AW, 2005. Health Information for International Travel 2005–2006. Philadelphia: Elsevier.
  6. Health Canada, 2004. Canadian recommendations for the prevention and treatment of malaria among international travelers. Can Commun Dis Rep 30 (S1): 1–62. [Google Scholar]
  7. Baird JK, Fryauff DJ, Hoffman SL, 2003. Primaquine for prevention of malaria in travelers. Clin Infect Dis 37 : 1659–1667. [Google Scholar]
  8. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL, Jeffery GM, 1955. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J Lab Clin Med 46 : 391–397. [Google Scholar]
  9. Alving AS, Rucker K, Flanagan CL, 1959. Observations on primaquine in the prophylaxis and cure of vivax malaria. Proc VI Int Congr Trop Med Malar, 203-9. Lisbon, September 1959.
  10. Powell RD, Brewer GJ, 1967. Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquine-resistant Plasmodium falciparum from Thailand. Am J Trop Med Hyg 16 : 693–698. [Google Scholar]
  11. Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL, 1995. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 171 : 1569–1575. [Google Scholar]
  12. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171 : 1678–1682. [Google Scholar]
  13. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, Ohrt CK, Mouzin E, Church CJ, Richards AL, Subianto B, Sandjaja B, Wignall FS, Hoffman SL. 1995. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 346 : 1190–1193. [Google Scholar]
  14. Soto J, Toledo J, Rodriguez M, Sanchez J, Herrera R, Padilla J, Berman J, 1998. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129 : 241–244. [Google Scholar]
  15. Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J, 1999. Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clin Infect Dis 29 : 199–201. [Google Scholar]
  16. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin, Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff DJ, Hoffman SL, and the United States Naval Medical Research Unit 2 Clinical Trials Team, 2001. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33 : 1990–1997. [Google Scholar]
  17. Barry M, 1999. Primaquine prophylaxis against malaria. Ann Intern Med 130 : 536–537. [Google Scholar]
  18. Collins WE, Jeffery GM, 1996. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 55 : 243–249. [Google Scholar]
  19. Schwartz E, Regev-Yochay G, 1999. Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. Clin Infect Dis 29 : 1502–1506. [Google Scholar]
  20. Heppner DG Jr, Gasser RA Jr, Kester KE, 1999. Primaquine prophylaxis against malaria. Ann Intern Med 130 : 536. [Google Scholar]
  21. Schwartz E, Parise M, Kozarsky P, Cetron M, 2003. Delayed onset of malaria—implications for chemoprophylaxis in travelers. N Engl J Med 349 : 1510–1516. [Google Scholar]
  22. Elliott JH, O’Brien D, Leder K, Kitchener S, Schwartz E, Weld L, Brown GV, Kain KC, Torresi J, 2004. Imported Plasmodium vivax malaria: demographic and clinical features in non-immune travelers. J Travel Med 11 : 213–217. [Google Scholar]
  23. Holtz TH, Kachur SP, MacArthur JR, Roberts JM, Barber AM, Steketee RW, Parise ME, 2001. Malaria surveillance—United States, 1998. Morbid Mortal Wkly Rep 50 (No. SS-5): 1–18. [Google Scholar]
  24. Causer LM, Newman RD, Barber AM, Roberts JM, Stennies G, Bloland PB, Parise ME, Steketee RW, 2002. Malaria surveillance—United States, 2000. Morbid Mortal Wkly Rep 51 (No. SS-5): 9–23. [Google Scholar]
  25. Newman RD, Barber AM, Roberts J, Holtz T, Steketee RW, Parise ME, 2002. Malaria surveillance—United States, 1999. Morbid Mortal Wkly Rep 51 (No. SS-1): 15–28. [Google Scholar]
  26. Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, Parise ME, Steketee RW, 2003. Malaria surveillance—United States, 2001. Morbid Mortal Wkly Rep 52 (No. SS-5): 1–14. [Google Scholar]
  27. Shah S, Filler S, Causer LM, Rowe AK, Bloland PB, Barber AM, Roberts JM, Desai MR, Parise ME, Steketee RW, 2004. Malaria surveillance—United States, 2002. Morbid Mortal Wkly Rep 53 (No. SS-1): 21–34. [Google Scholar]
  28. Eliades MJ, Shah S, Nguyen-Dinh P, Newman RD, Barber AM, Roberts JM, Mali S, Parise ME, Steketee R, 2005. Malaria surveillance—United States, 2003. Morbid Mortal Wkly Rep 54 (No. SS-2): 25–40. [Google Scholar]
  29. Skarbinski J, Eliades MJ, Causer LM, Barber AM, Mali S, Nguyen-Dinh P, Roberts JM, Parise ME, Slutsker L, Newman RD, 2006. Malaria surveillance—United States, 2004. Morbid Mortal Wkly Rep (No. SS-4): 23–37. [Google Scholar]
  30. Newman RD, Parise ME, Barber AM, Steketee RW, 2004. Malaria-related deaths among U.S. travelers, 1963–2001. Ann Intern Med 141 : 547–555. [Google Scholar]
  31. Committee to Advise on Tropical Medicine and Travel (CATMAT), 2000. Canadian recommendations for the prevention and treatment of malaria among international travelers. Can Commun Dis Rep 26 : 1–42. [Google Scholar]
  32. Centers for Disease Control and Prevention, 2001. Health Information for International Travel, 2001–2002. Atlanta, GA: US Department of Health and Human Services.
  33. Ehrman FC, Ellis JM, Young MD, 1945. Plasmodium vivax Chesson strain. Science 101 : 377. [Google Scholar]
  34. Edgcomb JH, Arnold J, Yount EH, Alving AS, Eichelberger L, 1950. Primaquine, SN 13272, a new curative agent in vivax malaria: A preliminary report. J Natl Malaria Soc 9 : 285–292. [Google Scholar]
  35. Ruhe DS, Cooper WC, Coatney GR, Josephson ES, 1949. Studies in human malaria. XV. The therapeutic action of pamaquine (plasmochin) against St. Elizabeth strain vivax malaria. Am J Hyg 49 : 367–373. [Google Scholar]
  36. Garrison PL, 1952. Status of primaquine. 2. Cure of Korean vivax malaria with pramaquine and primaquine. JAMA 149 : 1562–1563. [Google Scholar]
  37. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL, 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46 : 301–306. [Google Scholar]
  38. Clayman CB, Arnold J, Hockwold RS, Yount EH, Edgecomb JH, Alving AS, 1952. Toxicity of primaquine in caucasians. JAMA 149 : 1563–1568. [Google Scholar]
  39. Hockwald RS, Arnold J, Clayman CB, Alving AS, 1952. Toxicity of primaquine in Negroes. JAMA 149 : 1568–1570. [Google Scholar]
  40. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, 1960. Mitigation of the hemolytic effect of primaquine and enhancement of its action against erythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. A preliminary report. Bull World Health Organ 22 : 621. [Google Scholar]
  41. Clyde DF, Miller RM, DuPont HL, Hornick RB, 1971. Antimalarial effects of tetracyclines in man. J Trop Med Hyg 74 : 238–242. [Google Scholar]
  42. Cooper C, Myatt AV, Hernandez T, Jeffery GM, Coatney GR, 1953. Studies on human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883 and pamaquine as curative agents against sporozoite-induced Chesson strain vivax malaria. Am J Trop Med Hyg 2 : 949–957. [Google Scholar]
  43. Bradley JP, 1994. Drug-resistant Plasmodium vivax malaria. N Z Med J 107 : 228–229. [Google Scholar]
  44. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon A, Walsh DS, 1997. Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 91 : 939–943. [Google Scholar]
  45. Charoenlarp P, Harinasuta T, 1973. Relapses of vivax malaria after a conventional course of primaquine and chloroquine: Report of 2 cases. Southeast Asian J Trop Med Public Health 4 : 135–137. [Google Scholar]
  46. Krotoski WA, 1980. Frequency of relapse and primaquine resistance in Southeast Asian vivax malaria. N Engl J Med 303 : 587. [Google Scholar]
  47. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T, 1994. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 88 : 218–219. [Google Scholar]
  48. Kitchener S, Nasveld P, Bennett S, Torresi J, 2005. Adequate primaquine for vivax malaria. J Travel Med 12 : 133–135. [Google Scholar]
  49. Nayar JK, Baker RH, Knight JW, Sullivan JS, Morris CL, Richardson BB, Galland GG, Collins WE, 1997. Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys. J Parasitol 83 : 739–745. [Google Scholar]
  50. Garavelli PL, Corti E, 1992. Chloroquine resistance in Plasmodium vivax: The first case in Brazil. Trans R Soc Trop Med Hyg 86 : 128. [Google Scholar]
  51. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ, 2001. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 65 : 471–476. [Google Scholar]
  52. Arias AE, Corredor A, 1989. Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy. Trop Med Parasitol 40 : 21–23. [Google Scholar]
  53. Phillips EJ, Keystone JS, Kain KC, 1996. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis 23 : 1171–1173. [Google Scholar]
  54. Gascon J, Gomez Arce JE, Menendez C, Valls ME, Corachan M, 1994. Poor response to primaquine in two cases of Plasmodium vivax malaria from Guatemala. Trop Geogr Med 46 : 32–33. [Google Scholar]
  55. Smoak BL, DeFraites RF, Magill AJ, Kain KC, Wellde BT, 1997. Plasmodium vivax infections in U.S. Army troops: Failure of primaquine to prevent relapses in studies from Somalia. Am J Trop Med Hyg 56 : 231–234. [Google Scholar]
  56. Schwartz E, Regev-Yochay G, Kurnik D, 2000. Short report: A consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 62 : 393–395. [Google Scholar]
  57. Na DJ, Han JD, Cha DY, Song IK, Choi HW, Chung EA, Park CW, Choi JS, 1999. Imported tertian malaria resistant to primaquine. Korean J Intern Med 14 : 86–89. [Google Scholar]
  58. Spudick JM, Garcia LS, Graham DM, Haake DA, 2005. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin Microbiol 43 : 978–981. [Google Scholar]
  59. Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petruccelli BP, 2005. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 293 : 212–216. [Google Scholar]
  60. Doherty JF, Day JH, Warhurst DC, Chiodini PL, 1997. Treatment of Plasmodium vivax malaria—time for a change? Trans R Soc Trop Med Hyg 91 : 76. [Google Scholar]
  61. Miller LH, Wyler DJ, Glew RH, Collins WE, Contacos PG, 1974. Sensitivity of four Central American strains of Plasmodium vivax to primaquine. Am J Trop Med Hyg 23 : 309–310. [Google Scholar]
  62. Jelinek T, Nothdurft HD, von Sonnenburg F, Loscher T, 1995. Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg 52 : 322–324. [Google Scholar]
  63. Rombo L, Edwards G, Ward SA, Eriksson G, Lindquist L, Lindberg A, Runehagen A, Bjorkman A, Hylander NO, 1987. Seven patients with relapses of Plasmodium vivax or P. ovale despite primaquine treatment. Trop Med Parasitol 38 : 49–50. [Google Scholar]
  64. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F, 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 93 : 433–438. [Google Scholar]
  65. Saint-Yves IF, 1977. Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands. Papua New Guinea Med J 20 : 62–65. [Google Scholar]
  66. Luzzi GA, Warrell DA, Barnes AJ, Dunbar EM, 1992. Treatment of primaquine-resistant Plasmodium vivax malaria. Lancet 340 : 310. [Google Scholar]
  67. Clyde DF, McCarthy VC, 1977. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 26 : 562–563. [Google Scholar]
  68. Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39 : 1336–1345. [Google Scholar]
  69. Myat Phone K, Myint O, Aung N, Aye Lwin H, 1994. The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. Southeast Asian J Trop Med Public Health 25 : 710–713. [Google Scholar]
  70. Coatney GR, Getz ME, 1962. Primaquine and quinocide as curative agents against sporozoite-induced Chesson strain vivax malaria. Bull World Health Organ 27 : 290–293. [Google Scholar]
  71. Baird JK, Rieckmann KH, 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19 : 115–120. [Google Scholar]
  72. Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar NA, 1998. A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg 92 : 341. [Google Scholar]
  73. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA, 1999. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 93 : 809–812. [Google Scholar]
  74. Cedillos RA, Warren M, Jeffery GM, 1978. Field evaluation of primaquine in the control of Plasmodium vivax. Am J Trop Med Hyg 27 : 466–472. [Google Scholar]
  75. Contacos PG, Coatney GR, Collins WE, Briesch PE, Jeter MH, 1973. Five day primaquine therapy—an evaluation of radical curative activity against vivax malaria infection. Am J Trop Med Hyg 22 : 693–695. [Google Scholar]
  76. Baird JK, 1998. Primaquine as anti-relapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg 92 : 687. [Google Scholar]
  77. Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH, 2000. In-vivo sensitivity of Plasmodium vivax isolates from Rondnia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Ann Trop Med Parasitol 94 : 749–758. [Google Scholar]
  78. Rowland M, Durrani N, 1999. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg 93 : 641–643. [Google Scholar]
  79. Yadav RS, Ghosh SK, 2002. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. J Parasitol 88 : 1042–1044. [Google Scholar]
  80. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM, 1985. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 19 : 745–750. [Google Scholar]
  81. Price AH, Fletcher KA, 1986. Ethnic differences in the reactions to drugs and xenobiotics. The metabolism and toxicity of primaquine. Prog Clin Biol Res 214 : 261–278. [Google Scholar]
  82. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM, 1985. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol 19 : 751–755. [Google Scholar]
  83. Bhatia SC, Saraph YS, Revankar SN, Doshi KJ, Bharucha ED, Desai ND, Vaidya AB, Subrahmanyam D, Gupta KC, Satoskar RS, 1986. Pharmacokinetics of primaquine in patients with P. vivax malaria. Eur J Clin Pharmacol 31 : 205–210. [Google Scholar]
  84. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM, 1984. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17 : 441–446. [Google Scholar]
  85. Kennedy E, Frischer H, 1990. Distribution of primaquine in human blood: drug-binding to alpha 1-glycoprotein. J Lab Clin Med 116 : 871–878. [Google Scholar]
  86. Wernsdorfer WH, Trigg PI, 1984. Primaquine: Pharmacokinetics, Metabolism, Toxicity and Activity. New York: John Wiley & Sons.
  87. Bangchang KN, Karbwang J, Back DJ, 1992. Primaquine metabolism by human liver microsomes: Effect of other antimalarial drugs. Biochem Pharmacol 44 : 587–590. [Google Scholar]
  88. Parkhurst GW, Nora MV, Thomas RW, Carson PE, 1984. High-performance liquid chromatographic-ultraviolet determination of primaquine and its metabolites in human plasma and urine. J Pharm Sci 73 : 1329–1331. [Google Scholar]
  89. Greaves J, Evans DA, Gilles HM, Fletcher KA, Bunnag D, Harinasuta T, 1980. Plasma kinetics and urinary excretion of primaquine in man. Br J Clin Pharmacol 10 : 399–404. [Google Scholar]
  90. Back DJ, Purba HS, Park BK, Ward SA, Orme ML, 1983. Effect of chloroquine and primaquine on antipyrine metabolism. Br J Clin Pharmacol 16 : 497–502. [Google Scholar]
  91. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H, 1998. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28 : 1203–1253. [Google Scholar]
  92. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM, 2001. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29 : 30–35. [Google Scholar]
  93. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM, 2003. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59 : 429–442. [Google Scholar]
  94. Raaska K, Neuvonen PJ, 2000. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 56 : 585–589. [Google Scholar]
  95. Grasela TH Jr, Dreis MW, 1992. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system. Arch Intern Med 152 : 617–621. [Google Scholar]
  96. Bangchang KN, Karbwang J, Back DJ, 1992. Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. Biochem Pharmacol 43 : 1957–1961. [Google Scholar]
  97. Clyde DF, 1981. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 59 : 391–395. [Google Scholar]
  98. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM, 1999. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. Philadelphia: American College of Physicians.
  99. Singhasivanon V, Sabcharoen A, Attanath P, Chongsuphajaisiddhi T, Diquet B, Turk P, 1991. Pharmacokinetics of primaquine in healthy volunteers. Southeast Asian J Trop Med Public Health 22 : 527–533. [Google Scholar]
  100. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo, Leksana B, Masbar S, Richie TL, Jones TR, Tjitra E, Wignall FS, Hoffman SL, 1995. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 52 : 479–484. [Google Scholar]
  101. Phillips-Howard PA, Blaze M, Hurn M, Bradley DJ, 1986. Malaria prophylaxis: Survey of the response of British travellers to prophylactic advice. BMJ 293 : 932–934. [Google Scholar]
  102. Lobel HO, Phillips-Howard PA, Brandling-Bennett AD, Steffen R, Campbell CC, Houng AY, Were JBO, Moser R, 1990. Malaria incidence and prevention among European and North American travellers to Kenya. Bull World Health Organ 68 : 209–215. [Google Scholar]
  103. Hill DR, 2000. Health problems in a large cohort of Americans traveling to developing countries. J Travel Med 7 : 259–266. [Google Scholar]
  104. Rieckmann KH, Yeo AE, Davis DR, Hutton DC, Wheatley PF, Simpson R, 1993. Recent military experience with malaria chemoprophylaxis. Med J Aust 158 : 446–449. [Google Scholar]
  105. Newton JA, Schnepf GA, Wallace MR, Lobel HO, Kennedy CA, Oldfield ECI, 1994. Malaria in US marines returning from Somalia. JAMA 272 : 397–399. [Google Scholar]
  106. Powell RD, 1978. Chemoprophylaxis and malaria in American servicemen returning from Vietnam. Am J Trop Med Hyg 27 : 1–5. [Google Scholar]
  107. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M, 2004. Compliance with 14-day primaquine therapy for radical cure of vivax malaria—a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 98 : 168–173. [Google Scholar]
  108. World Health Organization Working Group, 1989. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 67 : 601–611. [Google Scholar]
  109. Beutler E, 1978. Hemolytic Anemia in Disorders of Red Cell Metabolism. New York: Plenum Press.
  110. Brewer GJ, Zarafonetis CJ, 1967. The haemolytic effect of various regimens of primaquine with chloroquine in American Negroes with G6PD deficiency and the lack of an effect of various antimalarial suppressive agents on erythrocyte metabolism. Bull World Health Organ 36 : 303–308. [Google Scholar]
  111. Charoenlarp P, Areekul S, Harinasuta T, Sirivorasarn P, 1972. The haemolytic effect of a single dose of 45 mg of primaquine in G-6-PD deficient Thais. J Med Assoc Thai 55 : 631–638. [Google Scholar]
  112. Pannacciulli I, Salvidio E, Tizianello A, Parravidino G, 1969. Hemolytic effects of standard single dosages of primaquine and chloroquine on G-6-PD-deficient caucasians. J Lab Clin Med 74 : 653–661. [Google Scholar]
  113. Reeve PA, Toaliu H, Kaneko A, Hall JJ, Ganczakowski M, 1992. Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency. J Trop Med Hyg 95 : 349–351. [Google Scholar]
  114. Aung Than B, Hla-Pe U, Thein T, 1970. Primaquine induced haemolysis in G-6-PD deficient Burmese. Trans R Soc Trop Med Hyg 64 : 785–786. [Google Scholar]
  115. Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, Chokjindachai W, Viriyavejakul P, Chalermrut K, Walsh DS, White J, 1999. Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 93 : 225–230. [Google Scholar]
  116. Charoenlarp P, Areekul S, Pholpothi T, Harinasuta T, 1973. The course of primaquine-induced haemolysis in G-6-PD-deficient Thais. J Med Assoc Thai 56 : 392–397. [Google Scholar]
  117. Beutler E, 1991. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 324 : 169–174. [Google Scholar]
  118. Khoo KK, 1981. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol 75 : 591–595. [Google Scholar]
  119. Karwacki JJ, Shanks GD, Kummalue T, Watanasook C, 1989. Primaquine induced hemolysis in a Thai soldier. Southeast Asian J Trop Med Public Health 20 : 555–556. [Google Scholar]
  120. Salvidio E, Pannacciulli I, Tizianello A, Ajmar F, 1967. Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. N Engl J Med 276 : 1339–1344. [Google Scholar]
  121. Beutler E, 1994. G6PD deficiency. Blood 84 : 3613–3636. [Google Scholar]
  122. Coleman MD, Coleman NA, 1996. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 14 : 394–405. [Google Scholar]
  123. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME, 1968. Methemo-globinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med 279 : 1127–1131. [Google Scholar]
  124. Fletcher KA, Evans DA, Gilles HM, Greaves J, Bunnag D, Harinasuta T, 1981. Studies on the pharmacokinetics of primaquine. Bull World Health Organ 59 : 407–412. [Google Scholar]
  125. Sietsma A, Naughton MA, Harley JD, 1971. Methaemoglobin levels in soldiers receiving antimalarial drugs. Med J Aust 1 : 473–475. [Google Scholar]
  126. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, Benowitz N, Wofsy CB, 1990. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 323 : 776–782. [Google Scholar]
  127. Sin DD, Shafran SD, 1996. Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 12 : 477–481. [Google Scholar]
  128. Paul MA, McCarthy AE, Gibson N, Kenny G, Cook T, Gray G, 2003. The impact of Malarone and primaquine on psychomotor performance. Aviat Space Environ Med 74 : 738–745. [Google Scholar]
  129. Schlossberg D, 1980. Reaction to primaquine. Ann Intern Med 92 : 435. [Google Scholar]
  130. Thong YH, Ferrante A, Rowan-Kelly B, 1978. Primaquine inhibits mitogen-induced human lymphocyte proliferative responses. Trans R Soc Trop Med Hyg 72 : 537–539. [Google Scholar]
  131. Ponnampalam JT, 1979. Immunosuppression caused by primaquine. Trans R Soc Trop Med Hyg 73 : 473–474. [Google Scholar]
  132. Prasad RN, Garg SK, Mahajan RC, Ganguly NK, 1990. Primaquine: Its effect on cellular immune response of normal rhesus monkeys. J Commun Dis 22 : 254–259. [Google Scholar]
  133. Thong YH, Ferrante A, Secker LK, 1981. Normal immunological responses in mice treated with chloroquine, quinine and primaquine. Trans R Soc Trop Med Hyg 75 : 108–109. [Google Scholar]
  134. Prasad RN, Virk KJ, Ganguly NK, Mahajan RC, 1991. Humoral immune response of normal rhesus monkeys during primaquine administration. J Commun Dis 23 : 240–244. [Google Scholar]
  135. Ferrante A, Goh DH, 1984. The effect of anti-malarial drugs on human natural killer cells in vitro. Parasite Immunol 6 : 571–580. [Google Scholar]
  136. Fryauff DJ, Mouzin E, Church LW, Ratiwayanto S, Hadiputranto H, Sutamihardja MA, Widjaja H, Corradin G, Subianto B, Hoffman SL, 1999. Lymphocyte response to tetanus toxin T-cell epitopes: Effects of tetanus vaccination and concurrent malaria prophylaxis. Vaccine 17 : 59–63. [Google Scholar]
  137. Fryauff DJ, Cryz SJ, Widjaja H, Mouzin E, Church LW, Sutamihardja MA, Richards AL, Subianto B, Hoffman SL, 1998. Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis. J Infect Dis 177 : 1762–1765. [Google Scholar]
  138. Fryauff DJ, Richards AL, Baird JK, Richie TL, Mouzin E, Tjitra E, Sutamihardja MA, Ratiwayanto S, Hadiputranto H, Lara-sati RP, Pudjoprawoto N, Subianto B, Hoffman SL, 1996. Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis. Antimicrob Agents Chemother 40 : 2737–2742. [Google Scholar]
  139. Fryauff DJ, Church LW, Richards AL, Widjaja H, Mouzin E, Ratiwayanto S, Hadiputranto H, Sutamihardja MA, Richie TL, Subianto B, Tjitra E, Hoffman SL, 1997. Lymphocyte response to tetanus toxoid among Indonesian men immunized with tetanus-diphtheria during extended chloroquine or primaquine prophylaxis. J Infect Dis 176 : 1644–1648. [Google Scholar]
  140. Fryauff DJ, Prodjodipuro P, Basri H, Jones TR, Mouzin E, Widjaja H, Subianto B, 1998. Intestinal parasite infections after extended use of chloroquine or primaquine for malaria prevention. J Parasitol 84 : 626–629. [Google Scholar]
  141. Brennecke FE, 1951. A preliminary report on the effect of certain 8-aminoquinolines in the treatment of rheumatoid arthritis. Lab Clin Med 38 : 795–796. [Google Scholar]
  142. Jones R Jr, Jackson LS, Di Lorenzo A, Marx RL, Levy BL, Kenny EC, Gilbert M, Johnston MN, Alving AS, 1953. Korean vivax malaria. III. Curative effect and toxicity of primaquine in doses from 10 to 30 mg. daily. Am J Trop Med Hyg 2 : 977–982. [Google Scholar]
  143. Sanofi-Synthelabo, 1999. Product Information: Primaquine Brand of Phosphate Tablets. New York: Sanofi-Synthelabo.
  144. USP DI Editorial Group, 2003. Primaquine (systemic). USP DI Drug Information for the Healthcare Provider. 23rd Edition. Taunton, MA: Micromedex, Inc.
  145. Jaeger A, Sauder P, Kopferschmitt J, Flesch F, 1987. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp 2 : 242–273. [Google Scholar]
  146. Kantor GS, 1992. Primaquine-induced methemoglobinemia during treatment of Pneumocystis carinii pneumonia. N Engl J Med 327 : 1461. [Google Scholar]
  147. Dawson AH, Whyte IM, 1989. Management of dapsone poisoning complicated by methaemoglobinaemia. Med Toxicol Adverse Drug Exp 4 : 387–392. [Google Scholar]
  148. Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, Cheung T, Soeiro R, Hojczyk P, Black JR, 1996. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 124 : 792–802. [Google Scholar]
  149. Ruf B, Rohde I, Pohle HD, 1991. Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia. Eur J Clin Mi-crobiol Infect Dis 10 : 207–210. [Google Scholar]
  150. Back DJ, Breckenridge AM, Grimmer SF, Orme ML, Purba HS, 1984. Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine. Contraception 30 : 289–295. [Google Scholar]
  151. 2002. Primaquine phosphate. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.
  152. White NJ, 1985. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10 : 187–215. [Google Scholar]
  153. 2001. The Use of Antimalarial Drugs. Report of a WHO Informal Consultation. Geneva: World Health Organization.
  154. Luzzi GA, Peto TEA, 1993. Adverse effects of anti-malarials. An update. Drug Saf 8 : 295–311. [Google Scholar]
  155. Chongsuphajaisiddhi T, 1988. Malaria in paediatric practice. Wernsdorfer W, McGregor I, eds. Malaria. Principles and Practice of Malariology. London: Churchill Livingstone, 889–902.
  156. Da Silva AR, Pedrozo Silva C M, Branco Mdos R, Branco Filho JR, 1989. [Results of the use of a therapeutic protocol for Plasmodium vivax for 5 days in 3 municipalities of the Sao Luis island, State of Maranhao, Brazil]. Rev Soc Bras Med Trop 22 : 131–136. [Google Scholar]
  157. Garfield RM, Vermund SH, 1983. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet 2 : 500–503. [Google Scholar]
  158. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A, 2000. Malaria eradication on islands. Lancet 356 : 1560–1564. [Google Scholar]
  159. Ministerio de Salud. Politica national de medicamentos para el control de la malaria en Peru. Lima, Peru, 1999. 37.
  160. Ministerio de Salud y Prevision Social, 2006. Manual de normas de tratamiento de la malaria. La Paz, Bolivia.
  161. Reeve PA, 1994. Malaria treatment in Vanuatu: new national treatment guidelines. Papua New Guinea Med J 37 : 181–188. [Google Scholar]
  162. American Academy of Pediatrics, 2000. 2000 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics.
  163. Cooke IF, 1985. Plasmodium vivax malaria in children. Med J Aust 142 : 490–491. [Google Scholar]
  164. Kramer MH, Lobel HO, 2001. Antimalarial chemoprophylaxis in infants and children. Paediatr Drugs 3 : 113–121. [Google Scholar]
  165. Matovcik LM, Junga IG, Schrier SL, 1985. Drug-induced en-docytosis of neonatal erythrocytes. Blood 65 : 1056–1063. [Google Scholar]
  166. Thatte HS, Schrier SL, 1988. Comparison of transferrin receptor-mediated endocytosis and drug-induced endocytosis in human neonatal and adult RBCs. Blood 72 : 1693–1700. [Google Scholar]
  167. Phillips-Howard PA, Wood D, 1996. The safety of antimalarial drugs in pregnancy. Drug Saf 14 : 131–145. [Google Scholar]
  168. Davis TM, 1998. Adverse effects of antimalarial prophylactic drugs: an important consideration in the risk-benefit equation. Ann Pharmacother 32 : 1104–1106. [Google Scholar]
  169. Briggs GG, Freeman RK, Yaffe SJ, 2002. Primaquine. Mitchell CW, ed. Drugs in Pregnancy and Lactation. Baltimore: Williams & Wilkins, 1154.
  170. Bryan JP, 2006. Cost considerations for malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. Am J Trop Med Hyg 75 : 416–420. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.75.402
Loading
/content/journals/10.4269/ajtmh.2006.75.402
Loading

Data & Media loading...

  • Received : 27 Jul 2005
  • Accepted : 13 Apr 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error